GOSS RSI Chart
Last 7 days
-2.7%
Last 30 days
-11.0%
Last 90 days
-32.4%
Trailing 12 Months
-44.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2022 | 966.5K | 1.2M | 1.4M | 1.6M |
2021 | 2.8M | 2.1M | 1.4M | 761.0K |
2020 | 5.0M | 4.5M | 4.0M | 3.4M |
2019 | 0 | 0 | 0 | 5.6M |
2018 | 0 | 0 | 0 | 1.7M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 27, 2024 | hasnain faheem | sold | -26,772 | 1.1554 | -23,172 | president & ceo |
Mar 27, 2024 | christian waage | sold | -7,429 | 1.1555 | -6,430 | evp, tech ops and admin |
Mar 27, 2024 | giraudo bryan | sold | -7,430 | 1.1556 | -6,430 | coo/cfo |
Mar 18, 2024 | peterson caryn | sold | -5,342 | 1.3297 | -4,018 | evp, regulatory affairs |
Mar 18, 2024 | aranda richard | sold | -5,341 | 1.3295 | -4,018 | chief medical officer |
Nov 15, 2023 | milligan sandra | bought | 25,212 | 0.7879 | 32,000 | - |
Nov 13, 2023 | giraudo bryan | bought | 112,880 | 0.5644 | 200,000 | coo/cfo |
Jul 24, 2023 | giraudo bryan | acquired | 98,316 | 1.82 | 54,020 | coo/cfo |
Jul 24, 2023 | hasnain faheem | acquired | 983,120 | 1.82 | 540,176 | president & ceo |
Jul 24, 2023 | christian waage | acquired | 24,577 | 1.82 | 13,504 | evp, tech ops and admin |
Which funds bought or sold GOSS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | added | 45.32 | 177,955 | 380,350 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -36.9 | -1,030,780 | 4,572,180 | -% |
May 15, 2024 | Eversept Partners, LP | reduced | -6.81 | 1,203,620 | 7,073,480 | 0.47% |
May 15, 2024 | Cubist Systematic Strategies, LLC | new | - | 165,298 | 165,298 | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | sold off | -100 | -3,792,350 | - | -% |
May 15, 2024 | Squarepoint Ops LLC | added | 546 | 311,663 | 354,040 | -% |
May 15, 2024 | Point72 Asia (Singapore) Pte. Ltd. | new | - | 62,039 | 62,039 | 0.02% |
May 15, 2024 | Schonfeld Strategic Advisors LLC | reduced | -51.16 | -124,255 | 213,058 | -% |
May 15, 2024 | Man Group plc | sold off | -100 | -346,642 | - | -% |
May 15, 2024 | D. E. Shaw & Co., Inc. | added | 16.97 | 237,074 | 699,609 | -% |
Unveiling Gossamer Bio Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Gossamer Bio Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.57 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Gossamer Bio Inc News
Income Statement (Quarterly) | |||||||||||||||
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2018Q4 |
Operating Expenses | -3.0% | 54,357,000 | 56,021,000 | 53,872,000 | 54,343,000 | 51,661,000 | 55,664,000 | 55,596,000 | 53,203,000 | 60,087,000 | 53,569,000 | 65,339,000 | 54,967,000 | 55,787,500 | 39,807,000 |
S&GA Expenses | 11.6% | 12,834,000 | 11,497,000 | 11,277,000 | 12,001,000 | 10,714,000 | 12,459,000 | 11,263,000 | 11,346,000 | 15,877,000 | 11,448,000 | 11,655,000 | 10,748,000 | 11,591,500 | 13,935,000 |
EBITDA Margin | - | - | - | -282 | -281 | -279 | - | - | -65.41 | -66.61 | -30.55 | -31.17 | -31.57 | -31.90 | -85.27 |
Interest Expenses | -0.5% | 3,457,000 | 3,475,000 | 3,481,000 | 3,467,000 | 4,937,000 | 4,889,000 | 4,834,000 | 4,780,000 | 4,753,000 | 4,715,000 | 2,491,000 | 707,000 | 1,084,000 | - |
EBT Margin | - | - | - | -307 | -307 | -307 | - | - | -70.70 | -70.70 | -32.41 | -32.41 | -32.41 | -32.41 | -85.45 |
Net Income | 6.1% | -55,764,000 | -59,363,000 | -56,466,000 | -57,785,000 | -56,284,000 | -60,247,000 | -59,832,000 | -57,641,000 | -64,604,000 | -57,812,000 | -66,870,000 | -54,074,000 | -54,698,000 | -38,794,000 |
Net Income Margin | 13.2% | -144 | -166 | -196 | -242 | -307 | -169 | -114 | - | - | - | - | - | - | - |
Free Cashflow | -29.2% | -47,832,000 | -37,028,000 | -48,942,000 | -53,640,000 | -40,592,000 | -42,558,000 | -47,588,000 | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -16.8% | 259 | 312 | 348 | 182 | 220 | 272 | 324 | 246 | 295 | 344 | 387 | 433 | 482 | 539 | 584 | 625 | 371 | 427 | 470 | 507 | 516 |
Current Assets | -16.7% | 255 | 307 | 341 | 173 | 210 | 262 | 312 | 233 | 281 | 332 | 374 | 417 | 466 | 522 | 566 | 608 | 355 | 409 | 452 | 490 | 498 |
Cash Equivalents | 21.0% | 39.00 | 32.00 | 83.00 | 37.00 | 65.00 | 112 | 153 | 94.00 | 139 | 183 | 214 | 343 | 440 | 487 | 462 | 486 | 111 | 135 | 131 | 149 | 171 |
Net PPE | -34.8% | 1.00 | 2.00 | 2.00 | 3.00 | 4.00 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 5.00 | 5.00 | 5.00 | 4.00 |
Liabilities | -6.6% | 233 | 249 | 243 | 245 | 248 | 260 | 267 | 262 | 265 | 222 | 217 | 212 | 210 | 219 | 212 | 205 | 65.00 | 74.00 | 71.00 | 66.00 | 36.00 |
Current Liabilities | -30.6% | 36.00 | 52.00 | 42.00 | 40.00 | 41.00 | 49.00 | 53.00 | 44.00 | 35.00 | 40.00 | 36.00 | 30.00 | 29.00 | 39.00 | 33.00 | 28.00 | 28.00 | 37.00 | 33.00 | 28.00 | 25.00 |
Long Term Debt | -100.0% | - | 1.00 | 4.00 | 6.00 | 9.00 | 12.00 | 15.00 | 18.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 28.00 | 28.00 | 28.00 | - |
LT Debt, Current | -17.4% | 10.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | -100.0% | - | 1.00 | 4.00 | 6.00 | 9.00 | 12.00 | 15.00 | 18.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 28.00 | 28.00 | 28.00 | - |
Shareholder's Equity | -57.4% | 27.00 | 63.00 | 105 | - | -28.46 | 12.00 | 56.00 | - | 30.00 | 121 | 170 | 221 | 272 | 321 | 372 | 420 | 306 | 352 | 399 | 441 | 480 |
Retained Earnings | -3.5% | -1,254 | -1,212 | -1,163 | -1,123 | -1,081 | -1,032 | -976 | -917 | -860 | -811 | -755 | -695 | -635 | -577 | -512 | -455 | -388 | -334 | -279 | -230 | -186 |
Additional Paid-In Capital | 0.5% | 1,281 | 1,275 | 1,269 | 1,062 | 1,053 | 1,045 | 1,033 | 901 | 891 | 933 | 925 | 915 | 907 | 898 | 885 | 875 | 695 | 686 | 678 | 672 | 667 |
Shares Outstanding | 0.4% | 226 | 225 | 225 | 95.00 | 95.00 | 94.00 | 91.00 | 77.00 | 76.00 | 75.00 | 75.00 | 75.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 98.00 | - | - | - | 541 | - | - | - | 517 | - | - | - | 775 | - | - | - | 948 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -56.5% | -52,302 | -33,424 | -34,494 | -38,251 | -52,989 | -47,730 | -36,997 | -48,822 | -53,483 | -40,509 | -42,035 | -47,450 | -58,896 | -36,736 | -44,930 | -42,399 | -52,295 | -44,140 | -36,110 | -36,810 | -27,774 |
Share Based Compensation | -3.7% | 5,811 | 6,032 | 6,162 | 8,197 | 8,127 | 11,449 | 10,122 | 9,999 | 10,983 | 7,659 | 7,587 | 8,054 | 8,708 | 12,681 | 8,923 | 8,900 | 8,244 | 6,862 | 5,728 | 5,140 | 3,089 |
Cashflow From Investing | 529.3% | 61,673 | -14,366 | -118,262 | 12,936 | 8,722 | 8,464 | -22,598 | 4,679 | 8,420 | 10,443 | -89,762 | -50,076 | 11,968 | 61,100 | 19,959 | 106,245 | 28,038 | 46,933 | 17,949 | -13,884 | -198,142 |
Cashflow From Financing | 12.0% | -2,555 | -2,903 | 198,497 | -2,904 | -2,536 | -2,873 | 119,221 | 21.00 | 721 | 371 | 1,913 | 271 | 774 | 249 | 891 | 310,829 | 571 | 1,518 | 369 | 28,347 | 291,344 |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 32,392 | $ 37,795 |
In process research and development | 0 | 15 |
General and administrative | 9,567 | 10,132 |
Total operating expenses | 41,959 | 47,942 |
Loss from operations | (41,959) | (47,942) |
Other income (expense) | ||
Interest income | 344 | 587 |
Interest expense | (3,129) | (3,500) |
Other income, net | 2,816 | 1,690 |
Total other income (expense), net | 31 | (1,223) |
Net loss | (41,928) | (49,165) |
Other comprehensive income (loss): | ||
Foreign currency translation | (119) | 23 |
Unrealized gain (loss) on marketable securities | (159) | 115 |
Other comprehensive income (loss) | (278) | 138 |
Comprehensive loss | $ (42,206) | $ (49,027) |
Net loss per share, basic (in dollars per share) | $ (0.19) | $ (0.52) |
Net loss per share, diluted (in dollars per share) | $ (0.19) | $ (0.52) |
Weighted average common shares outstanding, basic (in shares) | 225,735,236 | 94,870,293 |
Weighted average common shares outstanding, diluted (in shares) | 225,735,236 | 94,870,293 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 38,863 | $ 32,109 |
Marketable securities | 205,531 | 264,316 |
Prepaid expenses and other current assets | 10,875 | 10,094 |
Total current assets | 255,269 | 306,519 |
Property and equipment, net | 1,074 | 1,648 |
Operating lease right-of-use assets | 2,404 | 3,131 |
Other assets | 613 | 618 |
Total assets | 259,360 | 311,916 |
Current liabilities | ||
Accounts payable | 2,660 | 5,526 |
Accrued research and development expenses | 8,929 | 7,779 |
Current portion of long-term debt | 9,589 | 11,613 |
Accrued expenses and other current liabilities | 14,641 | 26,680 |
Total current liabilities | 35,819 | 51,598 |
Long-term convertible senior notes | 196,819 | 196,591 |
Long-term debt | 0 | 814 |
Operating lease liabilities - long-term | 0 | 144 |
Total liabilities | 232,638 | 249,147 |
Commitments and contingencies (Note 9) | ||
Stockholders' equity | ||
Common stock, $0.0001 par value; 700,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 226,218,653 shares issued and outstanding as of March 31, 2024, and 225,409,315 shares issued and outstanding as of December 31, 2023 | 23 | 23 |
Additional paid-in capital | 1,281,295 | 1,275,136 |
Accumulated deficit | (1,253,968) | (1,212,040) |
Accumulated other comprehensive loss | (628) | (350) |
Total stockholders' equity | 26,722 | 62,769 |
Total liabilities and stockholders' equity | $ 259,360 | $ 311,916 |